Chiesi Farmaceutici SpA - Company Profile
Powered by 
All the sales intelligence you need on Chiesi Farmaceutici SpA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Chiesi Farmaceutici SpA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Chiesi Farmaceutici SpA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Chiesi Farmaceutici SpA (Chiesi) researches, develops, produces, and commercialises novel medicines with a focus on respiratory, neonatology, rare disease and special care therapeutic areas. The company provides products for the treatment of chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, ankylosing spondylitis, hypertension, percutaneous coronary intervention, apnoea of prematurity, respiratory distress syndrome, lipoprotein lipase deficiency (LPLD), limbal stem cell deficiency (LSCD) and inflammatory bowel diseases, among others. The company operates production sites in Parma, Italy; Blois, France; and Santana De Parnaiba, Brazil; and conducts research and development activities in its R&D center in Parma and at laboratories in Paris (France), Chippenham (the UK), Cary (the US) and Lidingo (Sweden). Chiesi is headquartered in Parma, Emilia-Romagna, Italy.
Headquarters
Italy
Address
Via Palermo, 26/A, Parma, Emilia-Romagna, 43122
Website
www.chiesi.com
Telephone
39 0521 2791
No of Employees
7,686
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$3.7B
Chiesi Farmaceutici SpA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Rare Diseases | Atimos |
| Neonatology | Atem |
| Special Care | Beclospin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In June, the company entered into an agreement with Gossamer Bio to develop and commercialize seralutinib in pulmonary arterial hypertension and other respiratory indications. |
| 2024 | Contracts/Agreements | In May, the company entered into an agreement with Karolinska Institutet, to develop therapeutic solutions for urgent health challenges. |
| 2024 | Contracts/Agreements | In January, the company entered into an agreement with Oak Hill Bio to create, produce, and market OHB-607, a potentially revolutionary new-born treatment. |
Competitor Comparison
| Key Parameters | Chiesi Farmaceutici SpA | Recordati SpA | Cosmo Pharmaceuticals NV | Newron Pharmaceuticals SpA | FB Health SpA |
|---|---|---|---|---|---|
| Headquarters | Italy | Italy | Ireland | Italy | Italy |
| City | Parma | Milan | Dublin | Bresso | Ascoli Piceno |
| State/Province | Emilia-Romagna | - | - | - | Marche |
| No. of Employees | 7,686 | 4,693 | 325 | 27 | - |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Maria Paola Chiesi | Chairman | Executive Board | 2026 | - |
| Giuseppe Accogli | Director; Chief Executive Officer | Executive Board | 2023 | - |
| Alessandro Chiesi | Vice Chairman | Executive Board | 2026 | 60 |
| Alberto Chiesi | Director; President | Executive Board | - | 88 |
| Giacomo Chiesi | Director; Global Rare Diseases | Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer